Tag Archives: Servier

Symplmed Pharmaceuticals announced the FDA approval of Prestalia® for the treatment of hypertension licensed from Servier

Cincinnati, OH, 28-1-2015 — /EuropaWire/ — Symplmed Pharmaceuticals today announced the U.S. Food and Drug Administration (FDA) has approved Prestalia® (perindopril arginine and amlodipine) tablets for the treatment of hypertension licensed from Servier (Suresnes, France). Prestalia® is the first fixed-dose combination of … Read the full press release

Servier and Hybrigenics extend partnership to discover new drugs which inhibit Ubiquitin-Specific Proteases (USPs)

PARIS, 28-1-2015 — /EuropaWire/ — Hybrigenics (ALHYG), a bio-pharmaceutical company listed on the Alternext market of Euronext Paris, with a focus on research and development of new treatments for proliferative diseases, today announces the extension of its partnership with Servier to … Read the full press release

European pharmaceutical company Servier partners with Walter and Eliza Hall Institute to develop new agents that could be effective in treating several types of cancer

Melbourne, Australia and Suresnes, France, 2-10-2014 — /EuropaWire/ — The European pharmaceutical company Servier has established a collaborative partnership with the Walter and Eliza Hall Institute to facilitate the development of new agents that could be effective in treating several types of … Read the full press release

XENTION LTD announced the phase 2 development of its lead atrial fibrillation programme (“AF”) is underway

CAMBRIDGE, UK, 2-9-2014 — /EuropaWire/ — XENTION LTD (“Xention”), the Cambridge-based biopharmaceutical company specialising in the discovery and development of ion channel-modulating drugs developing anti-arrhythmic drugs, announced today that the phase 2 development of its lead atrial fibrillation programme (“AF”) is underway. … Read the full press release